Updated Data Demonstrate Significant Improvement in Hematologic Complete Response with DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
RARITAN, N.J., May 26, 2021 – The Janssen Pharmaceutical Companies of Johnson &Johnson today announced updated results from the Phase 3 ANDROMEDA study, which evaluated DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for the treatment of patients with newly diagnosed light chain (AL) amyloidosis, a rare blood cell disorder associated with the deterioration of vital organs, most notably the heart, kidneys and liver. Longer-term results from a median follow-up of 20.3 months showed rates of hematologic complete response (hemCR) remained significantly higher in patients treated with DARZALEX FASPRO® in combination with bortezomib (VELCADE®), cyclophosphamide and dexamethasone (D-VCd) compared to VCd alone (Abstract #8003). These data will be featured in an oral presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting on Tuesday, June 8. “Patients with AL amyloidosis, including those with advanced organ dysfunction, often face poor outcomes, and as many as 30 percent die within the first year of diagnosis,” said Efstathios Kastritis, M.D.*, Professor of Clinical Therapeutics at the National and Kapodistrian University of Athens School of Medicine, Athens, Greece and study investigator. “The longer-term results from the ANDROMEDA study show sustained overall deep hematologic responses and further establish the subcutaneous formulation of daratumumab as part of a new standard of care regimen in patients...
South African researchers report ‘extensive but incomplete’ reduction in immune protection
A South African study found that Omicron may dull the power of coronavirus vaccines, but hinted that booster shots might help.
A year ago today, Margaret Keenan became the first person in the world to receive the Pfizer/BioNTech covid-19 vaccine outside of a clinical trial. 12 months and billions of shots later, several countries are already on a third round of coronavirus vaccinations
In this study, we determined the incidence and risk factors of PPCs in elderly Thai patients who underwent upper abdominal procedures, and we investigated whether the Assess Respiratory Risk in Surgical Patients in Catalonia (ARISCAT) score helps to predict PPCs in Thais.MethodsA retrospective study was conducted on upper abdominal surgical patients aged over 65 years who had been admitted to the surgical ward of Siriraj Hospital, Mahidol University, Thailand, between January 2016 and December 2019. Data were collected on significant PPCs using the European Perioperative Clinical Outcome definitions. To identify risk facto...
Nearly all of Atrium Health's employees — 99.5% — are in compliance with the system's Covid-19 vaccination mandate, CEO Gene Woods said.
AbstractKey ContentCervical cancer is the commonest gynaecological malignancy diagnosed in pregnancy.Cancer symptoms may mimic complications of pregnancy, thus delaying diagnosis.Staging of cervical cancer in pregnancy is essential to determine an individual management plan.Treatment of cervical cancer in pregnancy is complex and depends on the stage of cancer and the gestation of the pregnancy.Involvement of a multidisciplinary team is essential in the care of a woman with cervical cancer in pregnancy.Learning ObjectivesTo understand how to diagnose, stage and treat cervical cancer in pregnancy.To know the risks to the fe...
The preprint study has not yet been peer reviewed and it tested 14 plasma samples from 12 vaccinated people, 6 of whom were previously infected. #pfizer #omicron #vaccinerecipients
ACR CONVERGENCE 2021—The ACR Convergence 2021 meeting reflected the continued advancement of science and practical research in the field of rheumatoid arthritis (RA). Among the most important topics this year in RA was the evolution of the risk-benefit profile of Janus kinase (JAK) inhibitors, for which new safety data emerged in a series of related... [Read More]
Studies are underway in test tubes and animals to determine whether the new Omicron variant of the coronavirus can slip past the immune protection of vaccination or a previous infection.
January 15, 2021 (HORSHAM, Pa.) – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today the U.S. Food and Drug Administration (FDA) approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj), a subcutaneous formulation of daratumumab, in combination with bortezomib, cyclophosphamide and dexamethasone (D-VCd) for the treatment of adult patients with newly diagnosed light chain (AL) amyloidosis. DARZALEX FASPRO® is the first and only FDA-approved treatment for patients with this blood cell disorder that is associated with the production of an abnormal protein, which leads to the...
More News: Acetaminophen | Allergy & Immunology | Amyloidosis | Anaphylactic Shock | Back Pain | Biotechnology | Blood Transusion | Brain | Cancer & Oncology | Cardiology | Cardiovascular | Child Development | Children | Clinical Trials | Constipation | Corticosteroid Therapy | Cough | Dexamethasone | Epidemiology | Greece Health | Hay Fever | Health Management | Heart | Heart Transplant | Hematology | Hypertension | Infectious Diseases | Insomnia | Kidney Transplant | Kidney Transplantation | Laboratory Medicine | Learning | Legislation | Liver | Liver Transplant | Lortab | Myeloma | Neurology | Neuroscience | Pain | Pain Management | Pharmaceuticals | Pneomococcal Vaccine | Pneumonia | Prednisone | Pregnancy | Pulmonary Hypertension | Rare Diseases | Respiratory Medicine | Revlimid | Science | Stem Cell Therapy | Stem Cells | Study | Thrombocytopenia | Toxicology | Transplant Surgery | Transplants | Universities & Medical Training | Urology & Nephrology | Vaccines | Velcade | Warnings | Women